Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476497 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
A Phase 1 study of Peanut Allergy, sponsored by Allergy Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 10
- Study locations
NCT05476497 is a Phase 1 study of Peanut Allergy that is active but no longer recruiting, run by Allergy Therapeutics. The registered enrollment target is 46 participants, below the 211-participant average among 13 other Peanut Allergy trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT05476497, a Phase 1 study of Peanut Allergy, is active but no longer recruiting, sponsored by Allergy Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLP Peanut
Study Locations (10)
Arizona
- University of Arizona - Tucson
Florida
- University of South Florida - Tampa
Kansas
- University of Kansas Medical Center - Kansas City
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05476497
The ClinicalTrials.gov registry entry for NCT05476497 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 13 other Peanut Allergy trials with a reported enrollment target (78% lower). The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05476497 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Arizona, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05476497 about?
NCT05476497 is a clinical study titled "Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects". This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the deg...
What is the current status of trial NCT05476497?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-10-17. Estimated completion is 2026-11.
What conditions does trial NCT05476497 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT05476497?
The interventions under investigation include: Placebo (BIOLOGICAL), VLP Peanut (BIOLOGICAL).
Who is sponsoring clinical trial NCT05476497?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05476497 being conducted?
This trial has 10 study locations across Arizona, Florida, Kansas, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
COMPLETED · Phase 1
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
COMPLETED · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.